2013
Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: A systematic review and meta-analysis of randomized trials
Obonska K, Navarese EP, Lansky A, Tarantini G, Rossini R, Kozinski M, Musumeci G, Di Pasquale G, Górny B, Szczesniak A, Kowalewski M, Gurbel PA, Kubica J. Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: A systematic review and meta-analysis of randomized trials. Atherosclerosis 2013, 229: 482-488. PMID: 23672879, DOI: 10.1016/j.atherosclerosis.2013.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdministration, OralAnticoagulantsDose-Response Relationship, DrugFactor Xa InhibitorsHumansRandomized Controlled Trials as TopicRisk FactorsConceptsAcute coronary syndromeRecent acute coronary syndromeOral factor Xa inhibitorsMajor bleeding complicationsNew oral anticoagulantsFactor Xa inhibitorsBleeding complicationsMajor bleedingCoronary syndromeOral anticoagulantsStandard therapyMyocardial infarctionOdds ratioXa inhibitorsSetting of ACSSystematic reviewAnti-Xa groupIntracranial bleeding ratesRecurrent MI ratesSecondary efficacy endpointsNew myocardial infarctionFactor X inhibitorsDose-related increaseEfficacy endpointPrimary endpoint
2012
Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial
Banai S, Finkelstein A, Almagor Y, Assali A, Hasin Y, Rosenschein U, Apruzzese P, Lansky AJ, Kume T, Edelman ER. Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial. American Heart Journal 2012, 165: 234-240.e1. PMID: 23351827, PMCID: PMC4637940, DOI: 10.1016/j.ahj.2012.10.023.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionLate lossCoronary interventionDiabetes mellitusPrimary efficacy end pointBare metal stent implantationEnd pointSystemic innate immunityEfficacy end pointPlacebo-controlled trialPrimary end pointAcute coronary syndromeStent late lossMetal stent implantationSingle intravenous bolusVascular injury sitesAverage late lossBaseline monocyteLiposomal alendronateCoronary syndromePlacebo groupStudy drugCoronary narrowingOverall cohortPrespecified subgroups
2010
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. Journal Of Invasive Cardiology 2010, 22: 2-6. PMID: 20048389.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngina, UnstableAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood PlateletsC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHeparinHumansImmunoglobulin Fab FragmentsMaleMiddle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsStentsTime FactorsTirofibanTyrosineConceptsPercutaneous coronary interventionC-reactive proteinTarget vessel revascularizationPlatelet inhibitionCoronary interventionLevels of CRPInflammatory markers C-reactive proteinPlatelet aggregationC-reactive protein levelsDouble-blind study designEfficacy of tirofibanLower platelet inhibitionCoronary artery bypassCoronary artery revascularizationArtery revascularizationDiabetic subsetEligible patientsNonfatal MIArtery bypassHs-CRPVessel revascularizationSpearman correlation coefficient modelClinical endpointsFirst time pointTirofiban
2009
Effect of Supersaturated Oxygen Delivery on Infarct Size After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Stone GW, Martin JL, de Boer MJ, Margheri M, Bramucci E, Blankenship JC, Metzger DC, Gibbons RJ, Lindsay BS, Weiner BH, Lansky AJ, Krucoff MW, Fahy M, Boscardin WJ. Effect of Supersaturated Oxygen Delivery on Infarct Size After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation Cardiovascular Interventions 2009, 2: 366-375. PMID: 20031745, DOI: 10.1161/circinterventions.108.840066.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionMajor adverse cardiovascular eventsElevation myocardial infarctionPercutaneous coronary interventionAdverse cardiovascular eventsAnterior ST-segment elevation myocardial infarctionInfarct sizeCoronary interventionMyocardial infarctionCardiovascular eventsLeft anteriorSymptom onsetLarge ST-segment elevation myocardial infarctionComposite major adverse cardiovascular eventsSestamibi single-photon emissionMedian infarct sizePosthoc subgroup analysisPrimary efficacy measureAcute myocardial infarctionPrimary safety measureSingle photon emissionNoninferior ratesTreat populationProtocol populationMulticenter trialImpact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial)
Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW. Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial). The American Journal Of Cardiology 2009, 103: 1196-1203. PMID: 19406258, DOI: 10.1016/j.amjcard.2009.01.030.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAge FactorsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsAntithrombinsCause of DeathDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationElectrocardiographyEnoxaparinFemaleFollow-Up StudiesHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProportional Hazards ModelsRecombinant ProteinsReference ValuesRisk AssessmentSeverity of Illness IndexSex FactorsSurvival AnalysisTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsElevation acute coronary syndromePercutaneous coronary interventionAcute coronary syndromeComposite ischemiaNet clinical outcomeMajor bleedingCoronary syndromeClinical outcomesNet clinical adverse eventsIIb/IIIa inhibitorsLate clinical outcomesCoronary artery bypassClinical adverse eventsImpact of genderACUITY trialBivalirudin monotherapyAntithrombotic therapyArtery bypassNon–STAdverse eventsAntithrombotic strategiesCoronary interventionIschemiaBivalirudin
2008
The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale
Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. American Heart Journal 2008, 156: 44-56. PMID: 18585496, DOI: 10.1016/j.ahj.2008.02.008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngioplasty, Balloon, CoronaryAnticoagulantsCombined Modality TherapyCoronary AngiographyDose-Response Relationship, DrugDrug Administration ScheduleDrug-Eluting StentsFollow-Up StudiesHeparin, Low-Molecular-WeightHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProspective StudiesRecombinant ProteinsReference ValuesResearch DesignRisk AssessmentStentsSurvival RateThrombosisTime FactorsConceptsPrimary PCIPrimary percutaneous coronary interventionIIb/IIIa inhibitorsAcute myocardial infarctionBare metal stentsGP IIb/IIIa inhibitorsHORIZONS-AMI trialUnfractionated heparinGlycoprotein IIb/IIIa inhibitorsIdentical bare-metal stentOverall event-free survivalAcute Myocardial Infarction trialEnd pointDirect thrombin inhibitor bivalirudinRoutine useEfficacy end pointMyocardial Infarction trialTarget lesion revascularizationEvent-free survivalClinical end pointsPercutaneous coronary interventionPaclitaxel-eluting stentsNew pharmacologic agentsThrombin inhibitor bivalirudinDrug-eluting stents
2004
Myocardial First-Pass Perfusion Magnetic Resonance Imaging
Wolff SD, Schwitter J, Coulden R, Friedrich MG, Bluemke DA, Biederman RW, Martin ET, Lansky AJ, Kashanian F, Foo TK, Licato PE, Comeau CR. Myocardial First-Pass Perfusion Magnetic Resonance Imaging. Circulation 2004, 110: 732-737. PMID: 15289374, DOI: 10.1161/01.cir.0000138106.84335.62.Peer-Reviewed Original ResearchMeSH KeywordsAdenosineAgedArea Under CurveCardiac CatheterizationContrast MediaCoronary AngiographyCoronary CirculationCoronary DiseaseDose-Response Relationship, DrugFalse Positive ReactionsFemaleGadolinium DTPAHumansHyperemiaMagnetic Resonance ImagingMaleMiddle AgedMyocardiumProspective StudiesROC CurveSensitivity and SpecificitySingle-Blind MethodConceptsObstructive coronary artery diseaseCoronary artery diseaseArtery diseaseFirst-pass perfusion magnetic resonance imagingReceiver-operating curve analysisHigher contrast dosesDose-ranging studyCoronary artery catheterizationLow-dose groupPerfusion magnetic resonance imagingQuantitative coronary angiographyFirst-pass perfusion imagingLeft ventricular myocardiumReceiver-operating curveMagnetic resonance imagingFirst-pass perfusion MRIGadopentetate dimeglumine injectionCoronary angiographyArtery catheterizationEfficacious doseClinical evaluationContrast doseMyocardial hyperemiaPerfusion defectsGadopentate dimeglumine
2003
Relation between the degree of procedural anticoagulation and complications after coronary stent implantation
Ashby DT, Dangas G, Aymong EA, Farkouh ME, Mehran R, Lansky AJ, Moses JW, Leon MB, Stone GW. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. The American Journal Of Cardiology 2003, 92: 319-322. PMID: 12888144, DOI: 10.1016/s0002-9149(03)00637-4.Peer-Reviewed Original Research
1999
Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion
Teirstein P, Mann J, Cundey P, Schechter E, Jacobs W, Grines C, Stagaman D, Lansky A, Hultquist M, Kusnick B, Heuser R, Kleinert H, Popma J. Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion. The American Journal Of Cardiology 1999, 83: 1623-1628. PMID: 10392865, DOI: 10.1016/s0002-9149(99)00163-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsCerebral HemorrhageChronic DiseaseCoronary AngiographyCoronary DiseaseDose-Response Relationship, DrugFemaleGraft Occlusion, VascularHeparinHumansInfusions, IntravenousMaleMiddle AgedPlasminogen ActivatorsRecombinant ProteinsSaphenous VeinUrokinase-Type Plasminogen ActivatorConceptsSaphenous vein graftsR-UKStudy drugVein graftsMyocardial infarctionNon-Q-wave myocardial infarctionPrimary study end pointSaphenous vein graft occlusionHigh-dose armStudy end pointLife-threatening bleedingVein graft occlusionHigh-dose groupDuration of infusionRecombinant urokinaseAcceptable success rateIntracerebral bleedPercutaneous revascularizationFinal angiogramGraft occlusionRecanalization rateAngiographic analysisHuman kidney cellsAllergic reactionsLow dose